

CORRECTED VERSION

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
26 February 2004 (26.02.2004)

PCT

(10) International Publication Number  
**WO 2004/016578 A3**

(51) International Patent Classification<sup>7</sup>: **C07C 217/10**,  
311/29, 213/00, 303/40, C07D 215/26, 213/65, 265/36,  
277/68

(21) International Application Number:  
PCT/EP2003/008264

(22) International Filing Date: 24 July 2003 (24.07.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0217225.2 25 July 2002 (25.07.2002) GB

(71) Applicant (for all designated States except US): **GLAXO  
GROUP LIMITED** [GB/GB]; Glaxo Wellcome House,  
Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BIGGADIKE,**  
**Keith** [GB/GB]; GlaxoSmithKline, Gunnels Wood Road,  
Stevenage, Hertfordshire SG1 2NY (GB). **COE, Diane,**  
**Mary** [GB/GB]; GlaxoSmithKline, Gunnels Wood Road,  
Stevenage, Hertfordshire SG1 2NY (GB). **HOLMES,**

**Duncan, Stuart** [GB/GB]; GlaxoSmithKline, Gunnels  
Wood Road, Stevenage, Hertfordshire SG1 2NY (GB).  
**LOOKER, Brian, Edgar** [GB/GB]; GlaxoSmithKline,  
Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY  
(GB).



(74) Agent: **FLORENCE, Julia, Anne**; GlaxoSmithKline,  
Corporate Intellectual Property (CN925.1), 980 Great  
West Road, Brentford, Middlesex TW8 9GS (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,  
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,  
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,

[Continued on next page]


(54) Title: ARYLETHANOLAMINE BETA2-ADRENORECEPTOR AGONIST COMPOUNDS




(a)



(b)



(c)



(d)

(57) **Abstract:** The present invention concerns compounds of formula (I) and salts, solvates, and physiologically functional derivatives thereof, wherein: R<sup>1</sup> is hydrogen or -XSO<sub>2</sub>NR<sup>6</sup>R<sup>7</sup>; R<sup>2</sup> and R<sup>3</sup> are independently selected from hydrogen, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, halo, phenyl and C<sub>1-6</sub> haloalkyl and Ar is a group selected from and. Processes for preparing said compounds and pharmaceutical formulations containing them are also described. Compounds of formula (I) are useful in the treatment of respiratory diseases



SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(48) Date of publication of this corrected version:

17 February 2005

Published:

— with international search report

(15) Information about Correction:

see PCT Gazette No. 07/2005 of 17 February 2005, Section II

(88) Date of publication of the International search report:

10 June 2004

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*